APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Antibody Service

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Recombinant Antibody Service Market Analysis and Forecast 2026-2032

12 April 2026237 pages

Choose your research edition.

Industry ResearchRecombinant Antibody Service Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Antibody Service Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Recombinant Antibody Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Antibody Service Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Recombinant Antibody Service Market Analysis and Forecast 2026-2032237 pages · $4,950 USD

Market perspective

The global Recombinant Antibody Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Recombinant Antibody Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Recombinant Antibody Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Recombinant Antibody Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Recombinant Antibody Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Recombinant Antibody Service include GenScript Biotech Corporation, Abcam plc, Creative Biolabs, Absolute Antibody Ltd., Thermo Fisher Scientific, ProteoGenix, Bio-Rad Laboratories, Rockland Immunochemicals Inc. and RayBiotech, Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Recombinant Antibody Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Recombinant Antibody Service, also provides the revenue of main regions and countries. Of the upcoming market potential for Recombinant Antibody Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Recombinant Antibody Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Recombinant Antibody Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Recombinant Antibody Service revenue, projected growth trends, production technology, application and end-user industry.

Recombinant Antibody Service Segment by Company

GenScript Biotech Corporation

Abcam plc

Creative Biolabs

Absolute Antibody Ltd.

Thermo Fisher Scientific

ProteoGenix

Bio-Rad Laboratories

Rockland Immunochemicals Inc.

RayBiotech, Inc.

Novoprotein Scientific Inc.

Sino Biological

Abnova

ACROBiosystems

Fitzgerald Industries International

Boster Biological Technology Co., Ltd.

Azenta Life Sciences

R&D Systems

Abcam

WuXi Biologics

Cell Signaling Technology, Inc.

Meridian Life Science Inc.

MabPlex Inc.

ProMab Biotechnologies

LakePharma(Curia)

Profacgen

Atlas Antibodies

Proteintech

BioLegend

OriGene Technologies

Biointron Biological

Detai Bio-Tech

FITGENE

Cusabio

GentleGen

TekBiotech

Recombinant Antibody Service Segment by Type

Antibody Discovery & Design Service

Recombinant Expression Service

Antibody Purification & Characterization Service

Recombinant Antibody Service Segment by Application

Biopharmaceuticals

Diagnostics

Research

Therapeutics

Recombinant Antibody Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Antibody Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Antibody Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Antibody Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Recombinant Antibody Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Recombinant Antibody Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Antibody Service revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Recombinant Antibody Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Antibody Discovery & Design Service Major Player Table 3. Recombinant Expression Service Major Player Table 4. Antibody Purification & Characterization Service Major Player Table 5. Global Recombinant Antibody Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Biopharmaceuticals Major Player Table 7. Diagnostics Major Player Table 8. Research Major Player Table 9. Therapeutics Major Player Table 10. Recombinant Antibody Service Industry Trends Table 11. Recombinant Antibody Service Industry Drivers Table 12. Recombinant Antibody Service Industry Opportunities and Challenges Table 13. Recombinant Antibody Service Industry Restraints Table 14. Global Recombinant Antibody Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Recombinant Antibody Service Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Recombinant Antibody Service Market Share by Region (2021-2026) Table 17. Global Recombinant Antibody Service Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Recombinant Antibody Service Market Share by Region (2027-2032) Table 19. Global Recombinant Antibody Service Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Recombinant Antibody Service Revenue Market Share by Players (2021-2026) Table 21. Global Recombinant Antibody Service Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Recombinant Antibody Service Key Players Headquarters & Area Served Table 23. Global Recombinant Antibody Service Players, Product Type & Application Table 24. Global Recombinant Antibody Service Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Recombinant Antibody Service by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Recombinant Antibody Service Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Recombinant Antibody Service Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Recombinant Antibody Service Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Recombinant Antibody Service Revenue Market Share by Type (2021-2026) Table 31. Global Recombinant Antibody Service Revenue Market Share by Type (2027-2032) Table 32. Global Recombinant Antibody Service Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Recombinant Antibody Service Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Recombinant Antibody Service Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Recombinant Antibody Service Revenue Market Share by Application (2021-2026) Table 36. Global Recombinant Antibody Service Revenue Market Share by Application (2027-2032) Table 37. GenScript Biotech Corporation Company Information Table 38. GenScript Biotech Corporation Business Overview Table 39. GenScript Biotech Corporation Recombinant Antibody Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. GenScript Biotech Corporation Recombinant Antibody Service Product Portfolio Table 41. GenScript Biotech Corporation Recent Development Table 42. Abcam plc Company Information Table 43. Abcam plc Business Overview Table 44. Abcam plc Recombinant Antibody Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Abcam plc Recombinant Antibody Service Product Portfolio Table 46. Abcam plc Recent Development Table 47. Creative Biolabs Company Information Table 48. Creative Biolabs Business Overview Table 49. Creative Biolabs Recombinant Antibody Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Creative Biolabs Recombinant Antibody Service Product Portfolio Table 51. Creative Biolabs Recent Development Table 52. Absolute Antibody Ltd. Company Information Table 53. Absolute Antibody Ltd. Business Overview Table 54. Absolute Antibody Ltd. Recombinant Antibody Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Absolute Antibody Ltd. Recombinant Antibody Service Product Portfolio Table 56. Absolute Antibody Ltd. Recent Development Table 57. Thermo Fisher Scientific Company Information Table 58. Thermo Fisher Scientific Business Overview Table 59. Thermo Fisher Scientific Recombinant Antibody Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Thermo Fisher Scientific Recombinant Antibody Service Product Portfolio Table 61. Thermo Fisher Scientific Recent Development Table 62. ProteoGenix Company Information Table 63. ProteoGenix Business Overview Table 64. ProteoGenix Recombinant Antibody Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. ProteoGenix Recombinant Antibody Service Product Portfolio Table 66. ProteoGenix Recent Development Table 67. Bio-Rad Laboratories Company Information Table 68. Bio-Rad Laboratories Business Overview Table 69. Bio-Rad Laboratories Recombinant Antibody Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Bio-Rad Laboratories Recombinant Antibody Service Product Portfolio Table 71. Bio-Rad Laboratories Recent Development Table 72. Rockland Immunochemicals Inc. Company Information Table 73. Rockland Immunochemicals Inc. Business Overview Table 74. Rockland Immunochemicals Inc. Recombinant Antibody Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Rockland Immunochemicals Inc. Recombinant Antibody Service Product Portfolio Table 76. Rockland Immunochemicals Inc. Recent Development Table 77. RayBiotech, Inc. Company Information Table 78. RayBiotech, Inc. Business Overview Table 79. RayBiotech, Inc. Recombinant Antibody Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. RayBiotech, Inc. Recombinant Antibody Service Product Portfolio Table 81. RayBiotech, Inc. Recent Development Table 82. Novoprotein Scientific Inc. Company Information Table 83. Novoprotein Scientific Inc. Business Overview Table 84. Novoprotein Scientific Inc. Recombinant Antibody Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Novoprotein Scientific Inc. Recombinant Antibody Service Product Portfolio Table 86. Novoprotein Scientific Inc. Recent Development Table 87. Sino Biological Company Information Table 88. Sino Biological Business Overview Table 89. Sino Biological Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Sino Biological Recombinant Antibody Service Product Portfolio Table 91. Sino Biological Recent Development Table 92. Abnova Company Information Table 93. Abnova Business Overview Table 94. Abnova Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Abnova Recombinant Antibody Service Product Portfolio Table 96. Abnova Recent Development Table 97. ACROBiosystems Company Information Table 98. ACROBiosystems Business Overview Table 99. ACROBiosystems Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. ACROBiosystems Recombinant Antibody Service Product Portfolio Table 101. ACROBiosystems Recent Development Table 102. Fitzgerald Industries International Company Information Table 103. Fitzgerald Industries International Business Overview Table 104. Fitzgerald Industries International Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Fitzgerald Industries International Recombinant Antibody Service Product Portfolio Table 106. Fitzgerald Industries International Recent Development Table 107. Boster Biological Technology Co., Ltd. Company Information Table 108. Boster Biological Technology Co., Ltd. Business Overview Table 109. Boster Biological Technology Co., Ltd. Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Boster Biological Technology Co., Ltd. Recombinant Antibody Service Product Portfolio Table 111. Boster Biological Technology Co., Ltd. Recent Development Table 112. Azenta Life Sciences Company Information Table 113. Azenta Life Sciences Business Overview Table 114. Azenta Life Sciences Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Azenta Life Sciences Recombinant Antibody Service Product Portfolio Table 116. Azenta Life Sciences Recent Development Table 117. R&D Systems Company Information Table 118. R&D Systems Business Overview Table 119. R&D Systems Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. R&D Systems Recombinant Antibody Service Product Portfolio Table 121. R&D Systems Recent Development Table 122. Abcam Company Information Table 123. Abcam Business Overview Table 124. Abcam Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. Abcam Recombinant Antibody Service Product Portfolio Table 126. Abcam Recent Development Table 127. WuXi Biologics Company Information Table 128. WuXi Biologics Business Overview Table 129. WuXi Biologics Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 130. WuXi Biologics Recombinant Antibody Service Product Portfolio Table 131. WuXi Biologics Recent Development Table 132. Cell Signaling Technology, Inc. Company Information Table 133. Cell Signaling Technology, Inc. Business Overview Table 134. Cell Signaling Technology, Inc. Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 135. Cell Signaling Technology, Inc. Recombinant Antibody Service Product Portfolio Table 136. Cell Signaling Technology, Inc. Recent Development Table 137. Meridian Life Science Inc. Company Information Table 138. Meridian Life Science Inc. Business Overview Table 139. Meridian Life Science Inc. Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 140. Meridian Life Science Inc. Recombinant Antibody Service Product Portfolio Table 141. Meridian Life Science Inc. Recent Development Table 142. MabPlex Inc. Company Information Table 143. MabPlex Inc. Business Overview Table 144. MabPlex Inc. Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 145. MabPlex Inc. Recombinant Antibody Service Product Portfolio Table 146. MabPlex Inc. Recent Development Table 147. ProMab Biotechnologies Company Information Table 148. ProMab Biotechnologies Business Overview Table 149. ProMab Biotechnologies Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 150. ProMab Biotechnologies Recombinant Antibody Service Product Portfolio Table 151. ProMab Biotechnologies Recent Development Table 152. LakePharma(Curia) Company Information Table 153. LakePharma(Curia) Business Overview Table 154. LakePharma(Curia) Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 155. LakePharma(Curia) Recombinant Antibody Service Product Portfolio Table 156. LakePharma(Curia) Recent Development Table 157. Profacgen Company Information Table 158. Profacgen Business Overview Table 159. Profacgen Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 160. Profacgen Recombinant Antibody Service Product Portfolio Table 161. Profacgen Recent Development Table 162. Atlas Antibodies Company Information Table 163. Atlas Antibodies Business Overview Table 164. Atlas Antibodies Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 165. Atlas Antibodies Recombinant Antibody Service Product Portfolio Table 166. Atlas Antibodies Recent Development Table 167. Proteintech Company Information Table 168. Proteintech Business Overview Table 169. Proteintech Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 170. Proteintech Recombinant Antibody Service Product Portfolio Table 171. Proteintech Recent Development Table 172. BioLegend Company Information Table 173. BioLegend Business Overview Table 174. BioLegend Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 175. BioLegend Recombinant Antibody Service Product Portfolio Table 176. BioLegend Recent Development Table 177. OriGene Technologies Company Information Table 178. OriGene Technologies Business Overview Table 179. OriGene Technologies Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 180. OriGene Technologies Recombinant Antibody Service Product Portfolio Table 181. OriGene Technologies Recent Development Table 182. Biointron Biological Company Information Table 183. Biointron Biological Business Overview Table 184. Biointron Biological Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 185. Biointron Biological Recombinant Antibody Service Product Portfolio Table 186. Biointron Biological Recent Development Table 187. Detai Bio-Tech Company Information Table 188. Detai Bio-Tech Business Overview Table 189. Detai Bio-Tech Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 190. Detai Bio-Tech Recombinant Antibody Service Product Portfolio Table 191. Detai Bio-Tech Recent Development Table 192. FITGENE Company Information Table 193. FITGENE Business Overview Table 194. FITGENE Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 195. FITGENE Recombinant Antibody Service Product Portfolio Table 196. FITGENE Recent Development Table 197. Cusabio Company Information Table 198. Cusabio Business Overview Table 199. Cusabio Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 200. Cusabio Recombinant Antibody Service Product Portfolio Table 201. Cusabio Recent Development Table 202. GentleGen Company Information Table 203. GentleGen Business Overview Table 204. GentleGen Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 205. GentleGen Recombinant Antibody Service Product Portfolio Table 206. GentleGen Recent Development Table 207. TekBiotech Company Information Table 208. TekBiotech Business Overview Table 209. TekBiotech Recombinant Antibody Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 210. TekBiotech Recombinant Antibody Service Product Portfolio Table 211. TekBiotech Recent Development Table 212. North America Recombinant Antibody Service Revenue by Type (2021-2026) & (US$ Million) Table 213. North America Recombinant Antibody Service Revenue by Type (2027-2032) & (US$ Million) Table 214. North America Recombinant Antibody Service Revenue by Application (2021-2026) & (US$ Million) Table 215. North America Recombinant Antibody Service Revenue by Application (2027-2032) & (US$ Million) Table 216. North America Recombinant Antibody Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 217. North America Recombinant Antibody Service Revenue by Country (2021-2026) & (US$ Million) Table 218. North America Recombinant Antibody Service Revenue by Country (US$ Million) & (2027-2032) Table 219. Europe Recombinant Antibody Service Revenue by Type (2021-2026) & (US$ Million) Table 220. Europe Recombinant Antibody Service Revenue by Type (2027-2032) & (US$ Million) Table 221. Europe Recombinant Antibody Service Revenue by Application (2021-2026) & (US$ Million) Table 222. Europe Recombinant Antibody Service Revenue by Application (2027-2032) & (US$ Million) Table 223. Europe Recombinant Antibody Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 224. Europe Recombinant Antibody Service Revenue by Country (2021-2026) & (US$ Million) Table 225. Europe Recombinant Antibody Service Revenue by Country (US$ Million) & (2027-2032) Table 226. China Recombinant Antibody Service Revenue by Type (2021-2026) & (US$ Million) Table 227. China Recombinant Antibody Service Revenue by Type (2027-2032) & (US$ Million) Table 228. China Recombinant Antibody Service Revenue by Application (2021-2026) & (US$ Million) Table 229. China Recombinant Antibody Service Revenue by Application (2027-2032) & (US$ Million) Table 230. Asia Recombinant Antibody Service Revenue by Type (2021-2026) & (US$ Million) Table 231. Asia Recombinant Antibody Service Revenue by Type (2027-2032) & (US$ Million) Table 232. Asia Recombinant Antibody Service Revenue by Application (2021-2026) & (US$ Million) Table 233. Asia Recombinant Antibody Service Revenue by Application (2027-2032) & (US$ Million) Table 234. Asia Recombinant Antibody Service Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 235. Asia Recombinant Antibody Service Revenue by Region (US$ Million) & (2021-2026) Table 236. Asia Recombinant Antibody Service Revenue by Region (US$ Million) & (2027-2032) Table 237. SAMEA Recombinant Antibody Service Revenue by Type (2021-2026) & (US$ Million) Table 238. SAMEA Recombinant Antibody Service Revenue by Type (2027-2032) & (US$ Million) Table 239. SAMEA Recombinant Antibody Service Revenue by Application (2021-2026) & (US$ Million) Table 240. SAMEA Recombinant Antibody Service Revenue by Application (2027-2032) & (US$ Million) Table 241. SAMEA Recombinant Antibody Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 242. SAMEA Recombinant Antibody Service Revenue by Country (2021-2026) & (US$ Million) Table 243. SAMEA Recombinant Antibody Service Revenue by Country (US$ Million) & (2027-2032) Table 244. Research Programs/Design for This Report Table 245. Authors List of This Report Table 246. Secondary Sources Table 247. Primary Sources List of Figures Figure 1. Recombinant Antibody Service Image Figure 2. Global Recombinant Antibody Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Antibody Service Market Size Share 2021 VS 2025 VS 2032 Figure 4. Antibody Discovery & Design Service Image Figure 5. Recombinant Expression Service Image Figure 6. Antibody Purification & Characterization Service Image Figure 7. Global Recombinant Antibody Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Recombinant Antibody Service Market Size Share 2021 VS 2025 VS 2032 Figure 9. Biopharmaceuticals Image Figure 10. Diagnostics Image Figure 11. Research Image Figure 12. Therapeutics Image Figure 13. Global Recombinant Antibody Service Market Size (US$ Million) & (2021-2032) Figure 14. Global Recombinant Antibody Service Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Recombinant Antibody Service Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Recombinant Antibody Service Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Recombinant Antibody Service Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Recombinant Antibody Service Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Recombinant Antibody Service Revenue Market Share by Type (2021-2032) Figure 21. Global Recombinant Antibody Service Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Recombinant Antibody Service Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Recombinant Antibody Service Revenue Market Share by Application (2021-2032) Figure 24. North America Recombinant Antibody Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Recombinant Antibody Service Revenue Share by Type (2021-2032) Figure 26. North America Recombinant Antibody Service Revenue Share by Application (2021-2032) Figure 27. North America Recombinant Antibody Service Revenue Share by Country (2021-2032) Figure 28. United States Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Recombinant Antibody Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Recombinant Antibody Service Revenue Share by Type (2021-2032) Figure 33. Europe Recombinant Antibody Service Revenue Share by Application (2021-2032) Figure 34. Europe Recombinant Antibody Service Revenue Share by Country (2021-2032) Figure 35. Germany Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Recombinant Antibody Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Recombinant Antibody Service Revenue Share by Type (2021-2032) Figure 45. China Recombinant Antibody Service Revenue Share by Application (2021-2032) Figure 46. Asia Recombinant Antibody Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Recombinant Antibody Service Revenue Share by Type (2021-2032) Figure 48. Asia Recombinant Antibody Service Revenue Share by Application (2021-2032) Figure 49. Asia Recombinant Antibody Service Revenue Share by Region (2021-2032) Figure 50. Japan Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Recombinant Antibody Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Recombinant Antibody Service Revenue Share by Type (2021-2032) Figure 58. SAMEA Recombinant Antibody Service Revenue Share by Application (2021-2032) Figure 59. SAMEA Recombinant Antibody Service Revenue Share by Country (2021-2032) Figure 60. Brazil Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Recombinant Antibody Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Antibody Discovery & Design Service
  • Recombinant Expression Service
  • Antibody Purification & Characterization Service
Applications
  • Biopharmaceuticals
  • Diagnostics
  • Research
  • Therapeutics
Companies covered
  • GenScript Biotech Corporation
  • Abcam plc
  • Creative Biolabs
  • Absolute Antibody Ltd.
  • Thermo Fisher Scientific
  • ProteoGenix
  • Bio-Rad Laboratories
  • Rockland Immunochemicals Inc.
  • RayBiotech, Inc.
  • Novoprotein Scientific Inc.
  • Sino Biological
  • Abnova
  • ACROBiosystems
  • Fitzgerald Industries International
  • Boster Biological Technology Co., Ltd.
  • Azenta Life Sciences
  • R&D Systems
  • Abcam
  • WuXi Biologics
  • Cell Signaling Technology, Inc.
  • Meridian Life Science Inc.
  • MabPlex Inc.
  • ProMab Biotechnologies
  • LakePharma(Curia)
  • Profacgen
  • Atlas Antibodies
  • Proteintech
  • BioLegend
  • OriGene Technologies
  • Biointron Biological
  • Detai Bio-Tech
  • FITGENE
  • Cusabio
  • GentleGen
  • TekBiotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Recombinant Antibody Service Market by Type
  3. 1.2.1 Global Recombinant Antibody Service Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Antibody Discovery & Design Service
  5. 1.2.3 Recombinant Expression Service
  6. 1.2.4 Antibody Purification & Characterization Service
  7. 1.3 Recombinant Antibody Service Market by Application
  8. 1.3.1 Global Recombinant Antibody Service Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Biopharmaceuticals
  10. 1.3.3 Diagnostics
  11. 1.3.4 Research
  12. 1.3.5 Therapeutics
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Recombinant Antibody Service Market Dynamics
  1. 2.1 Recombinant Antibody Service Industry Trends
  2. 2.2 Recombinant Antibody Service Industry Drivers
  3. 2.3 Recombinant Antibody Service Industry Opportunities and Challenges
  4. 2.4 Recombinant Antibody Service Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Recombinant Antibody Service Market Perspective (2021-2032)
  2. 3.2 Global Recombinant Antibody Service Growth Trends by Region
  3. 3.2.1 Global Recombinant Antibody Service Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Recombinant Antibody Service Market Size by Region (2021-2026)
  5. 3.2.3 Global Recombinant Antibody Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Recombinant Antibody Service Revenue by Players
  2. 4.1.1 Global Recombinant Antibody Service Revenue by Players (2021-2026)
  3. 4.1.2 Global Recombinant Antibody Service Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Recombinant Antibody Service Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Recombinant Antibody Service Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Recombinant Antibody Service Key Players Headquarters & Area Served
  7. 4.4 Global Recombinant Antibody Service Players, Product Type & Application
  8. 4.5 Global Recombinant Antibody Service Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Recombinant Antibody Service Market CR5 and HHI
  11. 4.6.3 2025 Recombinant Antibody Service Tier 1, Tier 2, and Tier 3
5 Recombinant Antibody Service Market Size by Type
  1. 5.1 Global Recombinant Antibody Service Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Recombinant Antibody Service Revenue by Type (2021-2032)
  3. 5.3 Global Recombinant Antibody Service Revenue Market Share by Type (2021-2032)
6 Recombinant Antibody Service Market Size by Application
  1. 6.1 Global Recombinant Antibody Service Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Recombinant Antibody Service Revenue by Application (2021-2032)
  3. 6.3 Global Recombinant Antibody Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 GenScript Biotech Corporation
  2. 7.1.1 GenScript Biotech Corporation Company Information
  3. 7.1.2 GenScript Biotech Corporation Business Overview
  4. 7.1.3 GenScript Biotech Corporation Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  5. 7.1.4 GenScript Biotech Corporation Recombinant Antibody Service Product Portfolio
  6. 7.1.5 GenScript Biotech Corporation Recent Developments
  7. 7.2 Abcam plc
  8. 7.2.1 Abcam plc Company Information
  9. 7.2.2 Abcam plc Business Overview
  10. 7.2.3 Abcam plc Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Abcam plc Recombinant Antibody Service Product Portfolio
  12. 7.2.5 Abcam plc Recent Developments
  13. 7.3 Creative Biolabs
  14. 7.3.1 Creative Biolabs Company Information
  15. 7.3.2 Creative Biolabs Business Overview
  16. 7.3.3 Creative Biolabs Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Creative Biolabs Recombinant Antibody Service Product Portfolio
  18. 7.3.5 Creative Biolabs Recent Developments
  19. 7.4 Absolute Antibody Ltd.
  20. 7.4.1 Absolute Antibody Ltd. Company Information
  21. 7.4.2 Absolute Antibody Ltd. Business Overview
  22. 7.4.3 Absolute Antibody Ltd. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Absolute Antibody Ltd. Recombinant Antibody Service Product Portfolio
  24. 7.4.5 Absolute Antibody Ltd. Recent Developments
  25. 7.5 Thermo Fisher Scientific
  26. 7.5.1 Thermo Fisher Scientific Company Information
  27. 7.5.2 Thermo Fisher Scientific Business Overview
  28. 7.5.3 Thermo Fisher Scientific Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Thermo Fisher Scientific Recombinant Antibody Service Product Portfolio
  30. 7.5.5 Thermo Fisher Scientific Recent Developments
  31. 7.6 ProteoGenix
  32. 7.6.1 ProteoGenix Company Information
  33. 7.6.2 ProteoGenix Business Overview
  34. 7.6.3 ProteoGenix Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  35. 7.6.4 ProteoGenix Recombinant Antibody Service Product Portfolio
  36. 7.6.5 ProteoGenix Recent Developments
  37. 7.7 Bio-Rad Laboratories
  38. 7.7.1 Bio-Rad Laboratories Company Information
  39. 7.7.2 Bio-Rad Laboratories Business Overview
  40. 7.7.3 Bio-Rad Laboratories Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Bio-Rad Laboratories Recombinant Antibody Service Product Portfolio
  42. 7.7.5 Bio-Rad Laboratories Recent Developments
  43. 7.8 Rockland Immunochemicals Inc.
  44. 7.8.1 Rockland Immunochemicals Inc. Company Information
  45. 7.8.2 Rockland Immunochemicals Inc. Business Overview
  46. 7.8.3 Rockland Immunochemicals Inc. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Rockland Immunochemicals Inc. Recombinant Antibody Service Product Portfolio
  48. 7.8.5 Rockland Immunochemicals Inc. Recent Developments
  49. 7.9 RayBiotech, Inc.
  50. 7.9.1 RayBiotech, Inc. Company Information
  51. 7.9.2 RayBiotech, Inc. Business Overview
  52. 7.9.3 RayBiotech, Inc. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  53. 7.9.4 RayBiotech, Inc. Recombinant Antibody Service Product Portfolio
  54. 7.9.5 RayBiotech, Inc. Recent Developments
  55. 7.10 Novoprotein Scientific Inc.
  56. 7.10.1 Novoprotein Scientific Inc. Company Information
  57. 7.10.2 Novoprotein Scientific Inc. Business Overview
  58. 7.10.3 Novoprotein Scientific Inc. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Novoprotein Scientific Inc. Recombinant Antibody Service Product Portfolio
  60. 7.10.5 Novoprotein Scientific Inc. Recent Developments
  61. 7.11 Sino Biological
  62. 7.11.1 Sino Biological Company Information
  63. 7.11.2 Sino Biological Business Overview
  64. 7.11.3 Sino Biological Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Sino Biological Recombinant Antibody Service Product Portfolio
  66. 7.11.5 Sino Biological Recent Developments
  67. 7.12 Abnova
  68. 7.12.1 Abnova Company Information
  69. 7.12.2 Abnova Business Overview
  70. 7.12.3 Abnova Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Abnova Recombinant Antibody Service Product Portfolio
  72. 7.12.5 Abnova Recent Developments
  73. 7.13 ACROBiosystems
  74. 7.13.1 ACROBiosystems Company Information
  75. 7.13.2 ACROBiosystems Business Overview
  76. 7.13.3 ACROBiosystems Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  77. 7.13.4 ACROBiosystems Recombinant Antibody Service Product Portfolio
  78. 7.13.5 ACROBiosystems Recent Developments
  79. 7.14 Fitzgerald Industries International
  80. 7.14.1 Fitzgerald Industries International Company Information
  81. 7.14.2 Fitzgerald Industries International Business Overview
  82. 7.14.3 Fitzgerald Industries International Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Fitzgerald Industries International Recombinant Antibody Service Product Portfolio
  84. 7.14.5 Fitzgerald Industries International Recent Developments
  85. 7.15 Boster Biological Technology Co., Ltd.
  86. 7.15.1 Boster Biological Technology Co., Ltd. Company Information
  87. 7.15.2 Boster Biological Technology Co., Ltd. Business Overview
  88. 7.15.3 Boster Biological Technology Co., Ltd. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Boster Biological Technology Co., Ltd. Recombinant Antibody Service Product Portfolio
  90. 7.15.5 Boster Biological Technology Co., Ltd. Recent Developments
  91. 7.16 Azenta Life Sciences
  92. 7.16.1 Azenta Life Sciences Company Information
  93. 7.16.2 Azenta Life Sciences Business Overview
  94. 7.16.3 Azenta Life Sciences Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Azenta Life Sciences Recombinant Antibody Service Product Portfolio
  96. 7.16.5 Azenta Life Sciences Recent Developments
  97. 7.17 R&D Systems
  98. 7.17.1 R&D Systems Company Information
  99. 7.17.2 R&D Systems Business Overview
  100. 7.17.3 R&D Systems Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  101. 7.17.4 R&D Systems Recombinant Antibody Service Product Portfolio
  102. 7.17.5 R&D Systems Recent Developments
  103. 7.18 Abcam
  104. 7.18.1 Abcam Company Information
  105. 7.18.2 Abcam Business Overview
  106. 7.18.3 Abcam Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Abcam Recombinant Antibody Service Product Portfolio
  108. 7.18.5 Abcam Recent Developments
  109. 7.19 WuXi Biologics
  110. 7.19.1 WuXi Biologics Company Information
  111. 7.19.2 WuXi Biologics Business Overview
  112. 7.19.3 WuXi Biologics Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  113. 7.19.4 WuXi Biologics Recombinant Antibody Service Product Portfolio
  114. 7.19.5 WuXi Biologics Recent Developments
  115. 7.20 Cell Signaling Technology, Inc.
  116. 7.20.1 Cell Signaling Technology, Inc. Company Information
  117. 7.20.2 Cell Signaling Technology, Inc. Business Overview
  118. 7.20.3 Cell Signaling Technology, Inc. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Cell Signaling Technology, Inc. Recombinant Antibody Service Product Portfolio
  120. 7.20.5 Cell Signaling Technology, Inc. Recent Developments
  121. 7.21 Meridian Life Science Inc.
  122. 7.21.1 Meridian Life Science Inc. Company Information
  123. 7.21.2 Meridian Life Science Inc. Business Overview
  124. 7.21.3 Meridian Life Science Inc. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Meridian Life Science Inc. Recombinant Antibody Service Product Portfolio
  126. 7.21.5 Meridian Life Science Inc. Recent Developments
  127. 7.22 MabPlex Inc.
  128. 7.22.1 MabPlex Inc. Company Information
  129. 7.22.2 MabPlex Inc. Business Overview
  130. 7.22.3 MabPlex Inc. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  131. 7.22.4 MabPlex Inc. Recombinant Antibody Service Product Portfolio
  132. 7.22.5 MabPlex Inc. Recent Developments
  133. 7.23 ProMab Biotechnologies
  134. 7.23.1 ProMab Biotechnologies Company Information
  135. 7.23.2 ProMab Biotechnologies Business Overview
  136. 7.23.3 ProMab Biotechnologies Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  137. 7.23.4 ProMab Biotechnologies Recombinant Antibody Service Product Portfolio
  138. 7.23.5 ProMab Biotechnologies Recent Developments
  139. 7.24 LakePharma(Curia)
  140. 7.24.1 LakePharma(Curia) Company Information
  141. 7.24.2 LakePharma(Curia) Business Overview
  142. 7.24.3 LakePharma(Curia) Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  143. 7.24.4 LakePharma(Curia) Recombinant Antibody Service Product Portfolio
  144. 7.24.5 LakePharma(Curia) Recent Developments
  145. 7.25 Profacgen
  146. 7.25.1 Profacgen Company Information
  147. 7.25.2 Profacgen Business Overview
  148. 7.25.3 Profacgen Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  149. 7.25.4 Profacgen Recombinant Antibody Service Product Portfolio
  150. 7.25.5 Profacgen Recent Developments
  151. 7.26 Atlas Antibodies
  152. 7.26.1 Atlas Antibodies Company Information
  153. 7.26.2 Atlas Antibodies Business Overview
  154. 7.26.3 Atlas Antibodies Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  155. 7.26.4 Atlas Antibodies Recombinant Antibody Service Product Portfolio
  156. 7.26.5 Atlas Antibodies Recent Developments
  157. 7.27 Proteintech
  158. 7.27.1 Proteintech Company Information
  159. 7.27.2 Proteintech Business Overview
  160. 7.27.3 Proteintech Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  161. 7.27.4 Proteintech Recombinant Antibody Service Product Portfolio
  162. 7.27.5 Proteintech Recent Developments
  163. 7.28 BioLegend
  164. 7.28.1 BioLegend Company Information
  165. 7.28.2 BioLegend Business Overview
  166. 7.28.3 BioLegend Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  167. 7.28.4 BioLegend Recombinant Antibody Service Product Portfolio
  168. 7.28.5 BioLegend Recent Developments
  169. 7.29 OriGene Technologies
  170. 7.29.1 OriGene Technologies Company Information
  171. 7.29.2 OriGene Technologies Business Overview
  172. 7.29.3 OriGene Technologies Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  173. 7.29.4 OriGene Technologies Recombinant Antibody Service Product Portfolio
  174. 7.29.5 OriGene Technologies Recent Developments
  175. 7.30 Biointron Biological
  176. 7.30.1 Biointron Biological Company Information
  177. 7.30.2 Biointron Biological Business Overview
  178. 7.30.3 Biointron Biological Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  179. 7.30.4 Biointron Biological Recombinant Antibody Service Product Portfolio
  180. 7.30.5 Biointron Biological Recent Developments
  181. 7.31 Detai Bio-Tech
  182. 7.31.1 Detai Bio-Tech Company Information
  183. 7.31.2 Detai Bio-Tech Business Overview
  184. 7.31.3 Detai Bio-Tech Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  185. 7.31.4 Detai Bio-Tech Recombinant Antibody Service Product Portfolio
  186. 7.31.5 Detai Bio-Tech Recent Developments
  187. 7.32 FITGENE
  188. 7.32.1 FITGENE Company Information
  189. 7.32.2 FITGENE Business Overview
  190. 7.32.3 FITGENE Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  191. 7.32.4 FITGENE Recombinant Antibody Service Product Portfolio
  192. 7.32.5 FITGENE Recent Developments
  193. 7.33 Cusabio
  194. 7.33.1 Cusabio Company Information
  195. 7.33.2 Cusabio Business Overview
  196. 7.33.3 Cusabio Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  197. 7.33.4 Cusabio Recombinant Antibody Service Product Portfolio
  198. 7.33.5 Cusabio Recent Developments
  199. 7.34 GentleGen
  200. 7.34.1 GentleGen Company Information
  201. 7.34.2 GentleGen Business Overview
  202. 7.34.3 GentleGen Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  203. 7.34.4 GentleGen Recombinant Antibody Service Product Portfolio
  204. 7.34.5 GentleGen Recent Developments
  205. 7.35 TekBiotech
  206. 7.35.1 TekBiotech Company Information
  207. 7.35.2 TekBiotech Business Overview
  208. 7.35.3 TekBiotech Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  209. 7.35.4 TekBiotech Recombinant Antibody Service Product Portfolio
  210. 7.35.5 TekBiotech Recent Developments
8 North America
  1. 8.1 North America Recombinant Antibody Service Revenue (2021-2032)
  2. 8.2 North America Recombinant Antibody Service Revenue by Type (2021-2032)
  3. 8.2.1 North America Recombinant Antibody Service Revenue by Type (2021-2026)
  4. 8.2.2 North America Recombinant Antibody Service Revenue by Type (2027-2032)
  5. 8.3 North America Recombinant Antibody Service Revenue Share by Type (2021-2032)
  6. 8.4 North America Recombinant Antibody Service Revenue by Application (2021-2032)
  7. 8.4.1 North America Recombinant Antibody Service Revenue by Application (2021-2026)
  8. 8.4.2 North America Recombinant Antibody Service Revenue by Application (2027-2032)
  9. 8.5 North America Recombinant Antibody Service Revenue Share by Application (2021-2032)
  10. 8.6 North America Recombinant Antibody Service Revenue by Country
  11. 8.6.1 North America Recombinant Antibody Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Recombinant Antibody Service Revenue by Country (2021-2026)
  13. 8.6.3 North America Recombinant Antibody Service Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Recombinant Antibody Service Revenue (2021-2032)
  2. 9.2 Europe Recombinant Antibody Service Revenue by Type (2021-2032)
  3. 9.2.1 Europe Recombinant Antibody Service Revenue by Type (2021-2026)
  4. 9.2.2 Europe Recombinant Antibody Service Revenue by Type (2027-2032)
  5. 9.3 Europe Recombinant Antibody Service Revenue Share by Type (2021-2032)
  6. 9.4 Europe Recombinant Antibody Service Revenue by Application (2021-2032)
  7. 9.4.1 Europe Recombinant Antibody Service Revenue by Application (2021-2026)
  8. 9.4.2 Europe Recombinant Antibody Service Revenue by Application (2027-2032)
  9. 9.5 Europe Recombinant Antibody Service Revenue Share by Application (2021-2032)
  10. 9.6 Europe Recombinant Antibody Service Revenue by Country
  11. 9.6.1 Europe Recombinant Antibody Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Recombinant Antibody Service Revenue by Country (2021-2026)
  13. 9.6.3 Europe Recombinant Antibody Service Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Recombinant Antibody Service Revenue (2021-2032)
  2. 10.2 China Recombinant Antibody Service Revenue by Type (2021-2032)
  3. 10.2.1 China Recombinant Antibody Service Revenue by Type (2021-2026)
  4. 10.2.2 China Recombinant Antibody Service Revenue by Type (2027-2032)
  5. 10.3 China Recombinant Antibody Service Revenue Share by Type (2021-2032)
  6. 10.4 China Recombinant Antibody Service Revenue by Application (2021-2032)
  7. 10.4.1 China Recombinant Antibody Service Revenue by Application (2021-2026)
  8. 10.4.2 China Recombinant Antibody Service Revenue by Application (2027-2032)
  9. 10.5 China Recombinant Antibody Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Recombinant Antibody Service Revenue (2021-2032)
  2. 11.2 Asia Recombinant Antibody Service Revenue by Type (2021-2032)
  3. 11.2.1 Asia Recombinant Antibody Service Revenue by Type (2021-2026)
  4. 11.2.2 Asia Recombinant Antibody Service Revenue by Type (2027-2032)
  5. 11.3 Asia Recombinant Antibody Service Revenue Share by Type (2021-2032)
  6. 11.4 Asia Recombinant Antibody Service Revenue by Application (2021-2032)
  7. 11.4.1 Asia Recombinant Antibody Service Revenue by Application (2021-2026)
  8. 11.4.2 Asia Recombinant Antibody Service Revenue by Application (2027-2032)
  9. 11.5 Asia Recombinant Antibody Service Revenue Share by Application (2021-2032)
  10. 11.6 Asia Recombinant Antibody Service Revenue by Country
  11. 11.6.1 Asia Recombinant Antibody Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Recombinant Antibody Service Revenue by Country (2021-2026)
  13. 11.6.3 Asia Recombinant Antibody Service Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Recombinant Antibody Service Revenue (2021-2032)
  2. 12.2 SAMEA Recombinant Antibody Service Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Recombinant Antibody Service Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Recombinant Antibody Service Revenue by Type (2027-2032)
  5. 12.3 SAMEA Recombinant Antibody Service Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Recombinant Antibody Service Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Recombinant Antibody Service Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Recombinant Antibody Service Revenue by Application (2027-2032)
  9. 12.5 SAMEA Recombinant Antibody Service Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Recombinant Antibody Service Revenue by Country
  11. 12.6.1 SAMEA Recombinant Antibody Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Recombinant Antibody Service Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Recombinant Antibody Service Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst